Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for Stroke Recovery
NCT07080567Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Maraviroc with Placebo (2 arms). Primary endpoint: Upper Extremity Fugl-Meyer Assessment at Day 90. Started Jul 2025; status: recruiting.
02
Drugs
maraviroc
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07080567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080567.